Answers are grounded in this paper and cite their sources.
Cholera toxin (CT) is a powerful immunomodulator with strong adjuvant activity. Much of this activity is retained by the binding component alone, cholera toxin B subunit (CTB). Little is known about the mechanism of the immunomodulatory activity of CTB. In this study, both CT and CTB were found to dramatically enhance IL-4 production from a T cell clone stimulated with antigen and the B cell hybridoma LB as antigen-presenting cell (APC). Enhancement of cytokine production was seen following pretreatment of the APC with CT or CTB, while pretreatment of the T cells had no effect. Furthermore, stimulatory activity on the APC was stable to fixation with paraformaldehyde, demonstrating that the activity was mediated by a surface molecule on the APC. CT-pretreated APC also enhanced IL-4 production from anti-CD3 mAb-stimulated T cells, indicating that CT was providing a co-stimulatory signal. CT treatment of LB cells did not alter the expression of class II MHC molecules, CTLA-4 counter-receptors, LFA-1 or ICAM-1. When mAb were raised against the CT-pretreated APC, the only antibodies that were found to inhibit IL-4 production were those specific for CTB itself. The antibodies blocked even when the CT or CTB were already bound to the APC, arguing that co-stimulation was provided by a direct interaction with CTB. Blocking experiments suggested that APC-associated CTB molecules are interacting with non-GM1 receptors on the T cells. This novel finding of CTB-mediated T-B interaction provides one of the first potential mechanisms for the adjuvant activity of CTB.
No takes yet. Share an insight, caveat, or question.
Li et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: